Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

Pharmaceutical

Catalyst Pharmaceuticals

Patrick J. McEnany 

Gary Ingenito

Jeff Del Carmen

Preethi Sundaram

Steven R. Miller

Alicia Grande

Brian Elsbernd

The Leadership Team at Catalyst Pharmaceuticals is responsible for steering the company's strategic direction and ensuring the successful development and commercialization of innovative treatments for rare diseases. They work collaboratively to align financial, regulatory, medical, and operational objectives, driving initiatives that prioritize patient needs while fostering a culture of compliance and scientific excellence. Through their collective expertise, this team guides the company in navigating the complexities of the biopharmaceutical landscape, ultimately aiming to enhance the lives of patients with unmet medical needs.

Leadership Team

Medical Affairs and Patient Advocacy

Board and Governance

Leadership Team

About

Team members

Other teams at Catalyst Pharmaceuticals

Medical Affairs and Patient Advocacy

Board and Governance